MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $53.67M rose 47.2% year over year, behind the +62.1% change in trailing-twelve-month research & development. Sequentially, it fell 6.6% from the prior quarter. Over 3 fiscal years it compounded at +69.0% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +47.2% toward the trailing-twelve-month pace of +62.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 202.86M USD
- Year-over-year change
- +79.9%
- 4-year CAGR
- +54.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 202.86M | +79.9% |
| FY2024 | 2024-12-31 | 112.77M | +254.6% |
| FY2023 | 2023-12-31 | 31.8M | -24.4% |
| FY2022 | 2022-12-31 | 42.05M | +18.4% |
| FY2021 | 2021-12-31 | 35.52M | — |
Research & Development vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's LTM Mar 2026 research & development of $220.82M is the 3rd highest of the 11 companies compared; the peer median is $92.68M.
- Its year-over-year change of +62.1% is the 2nd highest of 11, against a peer median of +37.6%.
- Over three fiscal years its annual growth of +69.0% compares with a peer median of +18.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M | -8.7% | +56.3% | 4685.4% |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
| LTM Jun 2026 | $175.6M | +66.9% | +70.5% | 9222.6% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $153.74M | +46.0% | +182.5% | — |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| FY2025 | $54.15M | +59.9% | — | 4011.3% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M | +48.2% | +21.1% | — |
| FY2025 | $37.8M | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $9.91M | -70.5% | -30.1% | — | |
| Peer median (excluding MLTX) | $92.68M | +37.6% | +18.6% | 4011.3% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.97K | 0 | 0 | 0 | 2.62M |
| Gross Profit | (4.97K) | 0 | 0 | 0 | (2.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.52M | 42.05M | 31.8M | 112.77M | 202.86M |
| Selling, General & Admin | 18.05M | 23.01M | 22.32M | 30.32M | 41.97M |
| Operating Expenses | 53.57M | 65.06M | 54.12M | 143.09M | 242.22M |
| Depreciation & Amortization | 4.97K | 164.78K | 370.32K | 1.38M | 2.62M |
| EBITDA | (53.63M) | (64.3M) | (43.61M) | (119.58M) | (219.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (53.58M) | (65.06M) | (54.12M) | (143.09M) | (244.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 7.25M |
| Other Income / Expenses | (61.85K) | 591.73K | 10.14M | 22.13M | 15.12M |
| Income Before Tax | (53.64M) | (64.47M) | (43.98M) | (120.96M) | (229.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 4.76K | 36.37K | 94.39K | 282.2K | 611K |
| Net Income | (53.64M) | (49.97M) | (36.01M) | (118.94M) | (227.32M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| EPS (Diluted) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| Weighted Avg Shares | 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
| Weighted Avg Shares (Diluted) | 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.